Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer

NCT07429318 | Active Not Recruiting

• 1 other identifier: NCC5964
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a single-center, retrospective cohort study. The purpose is to evaluate different perioperative treatment options on the efficacy and survival prognosis of locally advanced GC/GEJC, clarify whether the tumor regression grade can influence survival of patients using neoadjuvant therapy. Moreover, we aim to explore the clinical and pathological characteristics that will affect the long-term survival benefit of patients who underwent perioperative treatment.

Conditions

Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Outcome Measures

Primary Outcomes (1)

• OS

  overall survival

  From the start date of cycle 1 (each cycle is 14 days or 21 days) neoadjuvant therapy until the date of first documented death from any cause, assessed up to 100 months.

Secondary Outcomes (2)

• EFS

  From the start date of cycle 1 (each cycle is 14 days or 21 days) neoadjuvant therapy until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 100 months.

• DFS

  From the start date of cycle 1 (each cycle is 14 days or 21 days) adjuvant therapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.

Study Arms (2)

chemotherapy

patients who only used chemotherapy during neoadjuvant treatment

Procedure: Chemo only

immunochemotherapy

patients who used immunotherapy combined with chemotherapy during neoadjuvant treatment

Procedure: Immunochemotherapy

Interventions

Chemo only PROCEDURE

Patients who only used chemotherapy during neodajuvant treatment period

Also known as: chemothreapy

chemotherapy

Immunochemotherapy PROCEDURE

Patients who used immunotherapy combined with chemotherapy during neodajuvant treatment period

Also known as: immunotherapy combined with chemotherapy

immunochemotherapy

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients who had locally advanced GC/GEJC

You may qualify if:

• (1) Pathologically diagnosed as gastric adenocarcinoma or esophageal-gastric junction adenocarcinoma, and has not received any anti-tumor treatment before (such as surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.)
• (2) cT3-4N+M0 (according to AJCC version 8 stage) confirmed as resectable by CT or MRI.
• (3) Patients who underwent adjuvant therapy before surgery.
• (4) After neoadjuvant therapy , radical resection was performed at the Cancer Hospital of the Chinese Academy of Medical Sciences.
• (5) Patients who have complete clinical, pathological and imaging data.

You may not qualify if:

• (1) It is known that peritoneal metastasis or peritoneal irrigation solution cytology is positive (CY1P0) or there is distant metastasis (according to the 8th edition of AJCC).
• (2) There are unresectable factors, including irresectable tumor causes or surgical contraindications that are irresectable or refuse surgery.
• (3) Those who have suffered from other malignant tumors within 5 years or at the same time, except for cured skin basal cell carcinoma and cervical cancer in situ and breast cancer in situ.
• (4) Those who have had radiotherapy, interventional treatment and other local therapists before surgery.
• (5) Patients whose key diagnosis and treatment information records were missing.

Sponsors & Collaborators

• Cancer Institute and Hospital, Chinese Academy of Medical Sciences: lead

Study Sites (1)

Cancer Hodpital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, 100021, China

Location

MeSH Terms

Interventions

Drug Therapy

Intervention Hierarchy (Ancestors)

Therapeutics

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor

Study Record Dates

• First Submitted: January 28, 2026
• First Posted: February 24, 2026
• Study Start: January 1, 2026
• Primary Completion: June 30, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: February 24, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)